Choose your preferred way to stay informed of new case launches and settlement deadlines
Bolt announced in a press release on May 14, 2024, that the Company would "cease further development of trastuzumab imbotolimod (BDC-1001)", Bolt's lead asset, "and reduce workforce by approximately 50%". Following Bolt's announcement, multiple analysts downgraded the Company's stock. Following this news, Bolt's stock dropped over 18% on May 15, 2024.
In order to be eligible to join the BOLT class action lawsuit, you must have incurred a loss on shares of Bolt Biotherapeutics, Inc. purchased during the class period listed above.
TOP
